Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1280-1284

  Djulus, Josephine ^a   Koren, Gideon ^a,g   Einarson, Thomas R ^a   Wilton, Lynda ^b   Shakir, Saad ^b   Diav Citrin, Orna ^c   Kennedy, Deborah ^d   Lavigne, Sharon Voyer ^e   De Santis, Marco ^f   Einarson, Adrienne ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^c MINISTRY OF HEALTH   (Israel)

^d Mothersafe Program   (Australia)

^e Pregnancy Riskline   (United States)

^f Telefono Rosso   (Italy)

^g CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE;

ARTICLE; AUSTRALIA; BIRTH WEIGHT; CANADA; CONGENITAL MALFORMATION; CONTROLLED STUDY; DELIVERY; DEPRESSION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; ISRAEL; ITALY; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; STILLBIRTH; TERATOGENESIS; THERAPEUTIC ABORTION; UNITED STATES;

EID: 33748969679     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0817     Document Type: Article

References (15)

1. Remeron [package insert]. Roseland, NJ: Organon International Inc; 2005
2. Oliver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001;15:941-954
3. Saks BR. Mirtazapine: a treatment for depression, anxiety and hyperemesis gravidarum in the pregnant patient: a report of 7 cases. Arch Womens Ment Health 2001;3:165-170
4. Kesim M, Yaris F, Kadioglu M, et al. Mirtazapine use in two pregnant women: is it safe? [letter] Teratology 2002;66:204
5. Yaris F, Kadioglu M, Kesim M, et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235-238
6. Marcus SM, Flynn HA, Blow F, et al. A screening study of antidepressant treatment rates and mood symptoms in pregnancy. Arch Womens Ment Health 2005;8:25-27
7. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J Psychiatry Neurosci 2001;26:44-48
8. Bonari L, Koren G, Einarson TR, et al. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health 2005;8:214-220
9. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-827
10. Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005;39:803-809
11. Savitz DA, Hertz-Picciotto I, Poole C. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev 2002;24:91-101
12. Maconochie N, Doyle P, Prior S. The National Women's Health Study: assembly and description of a population-based reproductive cohort. BMC Public Health 2004;4:35
13. Lundy B, Jones NA, Field T, et al. Prenatal depression effects on neonates. Infant Behav Dev 1999;22:119-129
14. Beck CT. Postpartum depression predictors inventory-revised. Adv Neonatal Care 2003;3:47-48
15. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49:726-735